The report lands in your patient portal at 11:12 on a Tuesday night. You are 44, nine days out from surgery. On page two, one line stops you: chemotherapy recommended.
A big trial shared this spring says that line may be wrong for many women like you. It found that a gene test on your tumour can show whether chemotherapy would actually help. Many women with a low score did just as well on hormone pills alone.
| Who it covers | Women and men aged 40 or older with early, hormone-fuelled breast cancer, already told to have chemotherapy |
|---|---|
| What it found | About two in three had a low gene score, skipped chemotherapy and did just as well five years later |
| What it doesn't cover | Anyone under 40, and results beyond about four years |
Reading the report, line by line
"ER-positive, HER2-negative." Your cancer feeds on estrogen. It is the most common kind, and hormone pills will treat it for years.
"Lymph nodes: 2 of 14 positive." A little cancer reached the glands in your armpit. For a generation, that meant chemotherapy almost automatically.
"Chemotherapy recommended." This is the line OPTIMA tested. More than 4,400 people in six countries took part, led by researchers at University College London. Half followed the usual advice. The other half had their tumour tested first, and only those with a high score had chemotherapy.
Can a gene test tell you if you need chemo?
For this group, yes. The test, called Prosigna, reads 50 genes in the tumour that was already removed. It costs you no extra procedure, only a wait.
A low score means chemotherapy adds almost nothing. The researchers estimate that at most 2 in 100 low-score patients would gain anything from it. For a 44-year-old with a job and children at home, skipping it means keeping her hair, her energy and, often, her fertility. In Britain alone, more than 5,000 people a year could be spared.
If you're under 40
Many Viva readers are, and this result doesn't apply to you. Nobody under 40 was in the trial, and cancer in younger women often behaves differently. Another gene test, Oncotype DX, found that women before menopause did gain from chemotherapy.
Two more cautions apply to everyone. Hormone-fuelled cancer can return ten years later, and the trial has only about four years of results. It also hasn't been published in a medical journal yet.
Before you agree to anything, ask two things. Has my tumour had a gene test? Does the province pay for it? Coverage varies across Canada. Then write your score inside the hospital folder. For many women this year, that one number decided between months of chemotherapy and none.
Questions readers ask
What do I take instead of chemotherapy?
Hormone therapy, usually for five to ten years. It is most often a daily pill such as tamoxifen, letrozole or anastrozole. Women who haven't reached menopause may also get treatment that pauses the ovaries.
Is Prosigna the same as Oncotype DX?
No. They are different tests that look at different genes and give different scores. Your hospital may use either one. Ask which test you had, and what your score means in that test's own scale.
Does this apply to men?
Yes. Men with the same kind of early breast cancer could join the OPTIMA trial, so the results apply to them on the same terms. Men aged 40 or older should ask about a gene test too.
This article is for information and does not replace advice from your cancer care team.
Sources
- University College London: gene test can safely spare many patients chemotherapy, May 2026
- The ASCO Post: OPTIMA trial results
- The ASCO Post: OPTIMA five-year results, August 2026
